Chimeric Therapeutics Limited (CHM.AX)
AUD 0.01
(-14.29%)
AUD 0.01
(-14.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -3.05 Million AUD | 43.14% |
| 2023 | -5.36 Million AUD | 70.79% |
| 2022 | -18.38 Million AUD | 17.98% |
| 2021 | -22.41 Million AUD | -66193.13% |
| 2020 | 33.9 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -3.05 Million AUD | 13.4% |
| 2024 Q2 | -3.52 Million AUD | 0.0% |
| 2024 Q1 | -3.52 Million AUD | 80.82% |
| 2024 FY | -3.05 Million AUD | 43.14% |
| 2024 Q4 | -3.05 Million AUD | 0.0% |
| 2023 Q1 | -3.62 Million AUD | 80.27% |
| 2023 Q4 | -18.38 Million AUD | -242.32% |
| 2023 Q3 | -5.36 Million AUD | -48.08% |
| 2023 FY | -5.36 Million AUD | 70.79% |
| 2023 Q2 | -3.62 Million AUD | 0.0% |
| 2022 FY | -18.38 Million AUD | 17.98% |
| 2022 Q3 | -18.38 Million AUD | -36.86% |
| 2022 Q2 | -13.43 Million AUD | 0.0% |
| 2022 Q1 | -13.43 Million AUD | 40.07% |
| 2022 Q4 | -18.38 Million AUD | 0.0% |
| 2021 Q1 | 4.8 Million AUD | 0.0% |
| 2021 FY | -22.41 Million AUD | -66193.13% |
| 2021 Q4 | -22.41 Million AUD | 0.0% |
| 2021 Q3 | -22.41 Million AUD | -566.63% |
| 2021 Q2 | 4.8 Million AUD | 0.0% |
| 2020 FY | 33.9 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 83.845% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -210.862% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 160.249% |
| Biome Australia Limited | -1.56 Million AUD | -95.354% |
| Patrys Limited | -2.24 Million AUD | -36.254% |
| Orthocell Limited | -19.92 Million AUD | 84.677% |
| Imugene Limited | -91.56 Million AUD | 96.666% |
| Noxopharm Limited | -2.31 Million AUD | -31.599% |
| PYC Therapeutics Limited | -65.76 Million AUD | 95.357% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 69.959% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 51.722% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 50.801% |
| CSL Limited | 15.76 Billion AUD | 100.019% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 75.988% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -330.268% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 98.332% |
| Starpharma Holdings Limited | -19.83 Million AUD | 84.606% |
| Nanollose Limited | -96.22 Thousand AUD | -3072.773% |
| Memphasys Limited | 4.13 Million AUD | 173.827% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 49.328% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 38.375% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -67.417% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 96.15% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -146.526% |
| Race Oncology Limited | -17.18 Million AUD | 82.238% |
| Nyrada Inc. | -4.76 Million AUD | 35.987% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 97.114% |
| Dimerix Limited | -21.99 Million AUD | 86.118% |
| PharmAust Limited | -9.71 Million AUD | 68.571% |
| Immutep Limited | -122.18 Million AUD | 97.501% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 97.763% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 75.537% |
| BTC Health Limited | -2.02 Million AUD | -50.978% |
| Acrux Limited | -1.45 Million AUD | -109.397% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 82.14% |
| Biotron Limited | -386.06 Thousand AUD | -690.794% |
| Tissue Repair Ltd | -16.44 Million AUD | 81.431% |
| AdAlta Limited | -845.17 Thousand AUD | -261.228% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 83.564% |
| Hexima Limited | -2.22 Million AUD | -37.139% |
| AnteoTech Limited | -5 Million AUD | 38.959% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 82.635% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 10.104% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 42.712% |
| Actinogen Medical Limited | -9.13 Million AUD | 66.567% |
| Immuron Limited | -11.48 Million AUD | 73.415% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 80.814% |